Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cano Health, Inc. stock logo
CANO
Cano Health
$3.81
$1.74
$190.00
$12.39M0.05423,785 shs159,142 shs
Certara, Inc. stock logo
CERT
Certara
$16.45
-1.7%
$17.76
$11.81
$24.70
$2.64B1.63538,256 shs421,449 shs
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
$6.92
-1.8%
$7.36
$6.52
$8.65
$2.65B1.168,129 shs8,258 shs
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$14.03
-0.9%
$15.08
$11.03
$21.22
$1.79B1.1895,960 shs539,046 shs
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
$17.63
$17.63
$16.04
$22.99
$3.92B1.321.24 million shs5,400 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cano Health, Inc. stock logo
CANO
Cano Health
0.00%0.00%0.00%-13.58%+99.13%
Certara, Inc. stock logo
CERT
Certara
+3.53%-1.99%-3.57%+3.91%-31.24%
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
+1.66%-0.56%-6.37%-4.21%-15.77%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
+5.51%+2.24%-6.90%-10.66%-8.88%
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cano Health, Inc. stock logo
CANO
Cano Health
0.3558 of 5 stars
2.80.00.00.00.01.70.0
Certara, Inc. stock logo
CERT
Certara
3.7148 of 5 stars
3.20.00.04.31.12.51.9
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
3.1422 of 5 stars
0.03.02.50.02.81.72.5
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
2.349 of 5 stars
3.42.00.00.02.92.50.6
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cano Health, Inc. stock logo
CANO
Cano Health
1.67
Reduce$1.85∞ Upside
Certara, Inc. stock logo
CERT
Certara
2.36
Hold$20.0621.96% Upside
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
1.00
SellN/AN/A
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
2.80
Moderate Buy$19.5038.99% Upside
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
N/AN/AN/AN/A

Current Analyst Ratings

Latest NEO, EKTAY, CANO, CERT, and OCDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
Certara, Inc. stock logo
CERT
Certara
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Weight ➝ Overweight$23.00
4/4/2024
Certara, Inc. stock logo
CERT
Certara
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform
3/1/2024
Certara, Inc. stock logo
CERT
Certara
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$17.00 ➝ $20.00
3/1/2024
Certara, Inc. stock logo
CERT
Certara
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$14.00 ➝ $15.50
2/26/2024
Certara, Inc. stock logo
CERT
Certara
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
2/26/2024
Certara, Inc. stock logo
CERT
Certara
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$19.00
2/26/2024
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$18.00 ➝ $20.00
2/22/2024
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$17.00 ➝ $19.00
2/21/2024
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/21/2024
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.00 ➝ $24.00
1/25/2024
Certara, Inc. stock logo
CERT
Certara
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $18.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cano Health, Inc. stock logo
CANO
Cano Health
$2.74B0.00N/A0.03$100.28 per share0.00
Certara, Inc. stock logo
CERT
Certara
$354.34M7.44$0.96 per share17.08$6.55 per share2.51
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
$1.61B1.64$0.56 per share12.36$2.43 per share2.85
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$591.64M3.03$0.30 per share47.53$7.39 per share1.90
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
$2.04B1.92$2.28 per share7.73$1.99 per share8.86

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cano Health, Inc. stock logo
CANO
Cano Health
-$207.27M-$215.87N/AN/AN/A-18.62%-133.59%-19.18%N/A
Certara, Inc. stock logo
CERT
Certara
-$55.36M-$0.35N/A47.001.67-15.62%4.33%2.98%5/7/2024 (Confirmed)
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
$90.25M$0.3619.2214.72N/A7.88%15.16%5.01%N/A
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-$87.97M-$0.70N/AN/AN/A-14.87%-4.13%-2.33%4/30/2024 (Confirmed)
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
-$54.30M-$0.01N/A17.631.66-0.02%41.71%5.10%N/A

Latest NEO, EKTAY, CANO, CERT, and OCDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Certara, Inc. stock logo
CERT
Certara
$0.1030N/A-$0.1030N/AN/AN/A  
4/30/2024N/A
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-$0.0270N/A+$0.0270N/AN/AN/A  
2/29/2024Q4 2023
Certara, Inc. stock logo
CERT
Certara
$0.09$0.05-$0.04$0.18$86.80 million$88.01 million
2/29/2024Q3 2024
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
N/A$0.08+$0.08$0.08N/A$426.51 million
2/20/2024Q4 2023
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-$0.07-$0.02+$0.05$0.07$152.90 million$155.55 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cano Health, Inc. stock logo
CANO
Cano Health
N/AN/AN/AN/AN/A
Certara, Inc. stock logo
CERT
Certara
N/AN/AN/AN/AN/A
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
$0.162.31%N/A44.44%N/A
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
N/AN/AN/AN/AN/A
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
N/AN/AN/AN/AN/A

Latest NEO, EKTAY, CANO, CERT, and OCDX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/30/2024
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
$0.11462/26/20242/27/20243/18/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cano Health, Inc. stock logo
CANO
Cano Health
3.95
0.40
0.40
Certara, Inc. stock logo
CERT
Certara
0.28
2.62
2.62
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
0.57
1.12
0.83
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
0.57
6.20
5.95
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
4.91
1.89
1.29

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cano Health, Inc. stock logo
CANO
Cano Health
35.99%
Certara, Inc. stock logo
CERT
Certara
73.96%
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
N/A
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
98.50%
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
N/A

Insider Ownership

CompanyInsider Ownership
Cano Health, Inc. stock logo
CANO
Cano Health
13.93%
Certara, Inc. stock logo
CERT
Certara
2.60%
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
41.28%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
1.30%
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cano Health, Inc. stock logo
CANO
Cano Health
4,3655.41 million4.65 millionOptionable
Certara, Inc. stock logo
CERT
Certara
1,391160.19 million156.03 millionOptionable
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
4,540383.57 million225.23 millionNot Optionable
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
2,100127.67 million126.01 millionOptionable
Ortho Clinical Diagnostics Holdings plc stock logo
OCDX
Ortho Clinical Diagnostics
4,800222.59 millionN/ANot Optionable

NEO, EKTAY, CANO, CERT, and OCDX Headlines

SourceHeadline
Allergy & Clinical ImmunologyAllergy & Clinical Immunology
medscape.com - April 16 at 9:30 AM
Clinical Diagnostics & Research Virtual Event Series 2025Clinical Diagnostics & Research Virtual Event Series 2025
labroots.com - March 23 at 9:56 PM
Graduate Clinical RequirementsGraduate Clinical Requirements
slu.edu - March 10 at 3:20 PM
REM-Fit 500 Ortho mattress review: Firm, tailored support meets luxurious memory foamREM-Fit 500 Ortho mattress review: Firm, tailored support meets luxurious memory foam
t3.com - February 1 at 6:07 PM
Clinical Daily NewsClinical Daily News
mcknights.com - January 11 at 7:17 AM
Advancing Rapid Point-of-care Viral Diagnostics to a Clinical SettingAdvancing Rapid Point-of-care Viral Diagnostics to a Clinical Setting
medscape.com - December 9 at 6:17 PM
Clinical Diagnostics & Research Virtual Event Series 2018Clinical Diagnostics & Research Virtual Event Series 2018
labroots.com - October 13 at 7:31 PM
PsyD in Clinical PsychologyPsyD in Clinical Psychology
callutheran.edu - September 7 at 4:11 PM
Novacyt: Innovative Clinical DiagnosticsNovacyt: Innovative Clinical Diagnostics
investing.com - August 22 at 9:23 PM
Clinical Diagnostics & Research Virtual Event Series 2015Clinical Diagnostics & Research Virtual Event Series 2015
labroots.com - August 18 at 5:15 PM
Clinical Diagnostics & Research Virtual Event Series 2017Clinical Diagnostics & Research Virtual Event Series 2017
labroots.com - August 16 at 6:07 AM
First long COVID treatment clinical trials from NIH getting underwayFirst long COVID treatment clinical trials from NIH getting underway
cbsnews.com - August 9 at 8:53 AM
Clinical Differences Among Four Common Dementia SyndromesClinical Differences Among Four Common Dementia Syndromes
medscape.com - July 16 at 1:41 PM
The Intricacies of Western BlottingThe Intricacies of Western Blotting
the-scientist.com - June 14 at 5:34 AM
Next-generation Sequencing and its Applications in Molecular DiagnosticsNext-generation Sequencing and its Applications in Molecular Diagnostics
medscape.com - June 1 at 10:53 PM
Fully Automated LC-MS Designed for Clinical LabsFully Automated LC-MS Designed for Clinical Labs
technologynetworks.com - May 31 at 1:36 PM
Clinical ChallengesClinical Challenges
medpagetoday.com - May 24 at 3:08 PM
Cutting-edge DNA sequencing to speed diagnosticsCutting-edge DNA sequencing to speed diagnostics
pharmaphorum.com - May 21 at 1:51 PM
Sensors & DiagnosticsSensors & Diagnostics
rsc.org - May 3 at 9:12 AM
Johnson & Johnson sells its Ortho-Clinical Diagnostics unit for $4B. Whats next?Johnson & Johnson sells its Ortho-Clinical Diagnostics unit for $4B. What's next?
mddionline.com - April 21 at 10:50 PM
Multicolor FISH Methods in Current Clinical DiagnosticsMulticolor FISH Methods in Current Clinical Diagnostics
medscape.com - April 13 at 8:43 AM
Clinical Trial News and ResearchClinical Trial News and Research
news-medical.net - April 4 at 12:28 PM
News tagged with clinical trialsNews tagged with clinical trials
medicalxpress.com - March 25 at 8:56 AM
Quantum Dots: Heralding a Brighter Future for Clinical DiagnosticsQuantum Dots: Heralding a Brighter Future for Clinical Diagnostics
medscape.com - March 20 at 8:46 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Cano Health logo

Cano Health

NYSE:CANO
Cano Health, Inc. provides primary care medical services to its members in the United States and Puerto Rico. It owns and operates medical centers enabled by CanoPanorama, a proprietary population health management technology-powered platform that provides the healthcare providers at its medical centers with a 360-degree view of their members with actionable insights to improve care decisions and member engagement. The company also operates pharmacies, as well as provides dental services in its medical centers. Cano Health, Inc. was founded in 2009 and is headquartered in Miami, Florida.
Certara logo

Certara

NASDAQ:CERT
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Elekta AB (publ) logo

Elekta AB (publ)

OTCMKTS:EKTAY
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
NeoGenomics logo

NeoGenomics

NASDAQ:NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Ortho Clinical Diagnostics logo

Ortho Clinical Diagnostics

NASDAQ:OCDX
Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey.